[go: up one dir, main page]

WO1996041634A3 - Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection - Google Patents

Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection Download PDF

Info

Publication number
WO1996041634A3
WO1996041634A3 PCT/EP1996/002540 EP9602540W WO9641634A3 WO 1996041634 A3 WO1996041634 A3 WO 1996041634A3 EP 9602540 W EP9602540 W EP 9602540W WO 9641634 A3 WO9641634 A3 WO 9641634A3
Authority
WO
WIPO (PCT)
Prior art keywords
association
treatment
nucleoside
hiv infection
reverse transcriptase
Prior art date
Application number
PCT/EP1996/002540
Other languages
French (fr)
Other versions
WO1996041634A2 (en
Inventor
Colla Paolo La
Maria Elena Marongiu
Giovanna Piras
Original Assignee
Sardinian Antiviral Research C
Colla Paolo
Maria Elena Marongiu
Giovanna Piras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sardinian Antiviral Research C, Colla Paolo, Maria Elena Marongiu, Giovanna Piras filed Critical Sardinian Antiviral Research C
Priority to AU63552/96A priority Critical patent/AU6355296A/en
Publication of WO1996041634A2 publication Critical patent/WO1996041634A2/en
Publication of WO1996041634A3 publication Critical patent/WO1996041634A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of a non-nucleoside reverse transcriptase inhibitor is described, in particular of derivatives of 6-benzyl-4-oxopyrimidine having general formula (I), in which X is selected from the group consisting of O, S; R is selected from the group consisting of alkyl from C1 to C4, cycloalkyl C5 and C6; R', R' and Z, equal or different among them may be H, alkyl from C1 to C4 considering that when X is equal to 0, R and R' cannot be both equal to H, their pharmaceutically acceptable salts and their soluble derivatives, in association with nucleoside inhibitors selected from the group consisting of AZT, d4T and their phosphodiester or phosphotriester derivatives, for the treatment of HIV infection. Pharmaceutical compositions useful for the treatment of HIV infection consisting of the association of different components are also described.
PCT/EP1996/002540 1995-06-13 1996-06-12 Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection WO1996041634A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63552/96A AU6355296A (en) 1995-06-13 1996-06-12 Use of a non-nucleoside reverse transcriptase inhibitor in a ssociation with nucleoside inhibitors for the treatment of h iv infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95CA000009A IT1281502B1 (en) 1995-06-13 1995-06-13 USE OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR IN COMBINATION WITH NUCLEOSIDE INHIBITORS FOR THE TREATMENT OF
ITCA95A000009 1995-06-13

Publications (2)

Publication Number Publication Date
WO1996041634A2 WO1996041634A2 (en) 1996-12-27
WO1996041634A3 true WO1996041634A3 (en) 1997-01-23

Family

ID=11347060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002540 WO1996041634A2 (en) 1995-06-13 1996-06-12 Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection

Country Status (3)

Country Link
AU (1) AU6355296A (en)
IT (1) IT1281502B1 (en)
WO (1) WO1996041634A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (en) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Pharmaceutical formulations of efavirenz and disintegrants providing for increasing dissolution rate and process of manufacturing such tablets or capsules
AU6111000A (en) * 1999-07-22 2001-02-13 Vertex Pharmaceuticals Incorporated Inhibitors of viral helcase
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
KR20120090034A (en) 2009-07-24 2012-08-16 벤더르빌트 유니버시티 Isoform selective phospholipase d inhibitors
CA2850597A1 (en) 2011-09-30 2013-04-04 Vanderbilt University Antiviral therapies with phospholipase d inhibitors
US20140163055A1 (en) * 2012-12-11 2014-06-12 Vanderbilt University Methods and compositions of treating hiv infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRAMONTANO E ET AL: "Characterization of the anti-HIV-1 activity of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors", MICROBIOLOGICA (PAVIA), 17 (4). 1994. 269-279., XP000609825 *

Also Published As

Publication number Publication date
WO1996041634A2 (en) 1996-12-27
AU6355296A (en) 1997-01-09
ITCA950009A0 (en) 1995-06-13
ITCA950009A1 (en) 1996-12-13
IT1281502B1 (en) 1998-02-18

Similar Documents

Publication Publication Date Title
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
EP2272516A3 (en) 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor
CA2434906A1 (en) Use of an adenosine a3 receptor agonist for inhibition of viral replication
EP0707481A4 (en)
YU13695A (en) Application of 2-phenyl-3-aroylbenzothiophene and pharmaceutical formulations thereof
NO953844D0 (en) 1-amidinophenyl pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
ATE250623T1 (en) 4'-C-ETHYNYL PURINE NUCLEOSIDES
CA2067381A1 (en) Treatment of hiv infections and compounds useful therein
CA2068790A1 (en) Antiviral compounds
AU8693491A (en) Synergism of hiv reverse transcriptase inhibitors
NZ229453A (en) A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
ES2108717T3 (en) DERIVATIVES OF THE TETRAHIDROPIRROLO (1,2-A) PIRAZINA-4-ESPIRO-3'-PIRROLIDINA, PROCEDURES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
HUP0202191A2 (en) Substituted polycyclic aryl and heteroaryl pirazinones useful for selective inhibition of the coagulation cascade and pharmaceutical compositions containing them
WO1996030370A3 (en) Thiazole and thiadiazole derivatives, their preparation and pharmaceutical compositions useful in the treatment of thrombocytopenia
CA2364251A1 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
WO1996041634A3 (en) Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection
AU2001278708A1 (en) Adenosine derivatives and use thereof
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
WO1999019304A3 (en) Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors
YU6396A (en) COMBINATION OF HIV PROTEASE INHIBITORS WITH OTHER UNITS FOR HIV INFECTION THERAPY
EP1065200A4 (en) Aminoisoquinoline derivatives
NO983444L (en) Benzo (c) quinolizine derivatives, their preparation and use as 5 <alfa> reductase inhibitors
CA2213099A1 (en) S-(+)-adenosylmethionine and 3'-azido-2',3'-dideoxy-nucleoside complexes as potent inhibitors of hiv-replication
WO2003016266A1 (en) β-KETOAMIDE COMPOUNDS AND MEDICINAL USE THEREOF
CA2183234A1 (en) Agent for prophylaxis and treatment of thromboxane a2-mediated diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA